Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability

Psoriasis

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

J Eur Acad Dermatol Venereol

Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, Bansal A, Dahale SS, Martin R, Paguet B, Magnolo N, Kingo K

doi: 10.1111/jdv.70155

Psoriasis

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

J Eur Acad Dermatol Venereol

Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J, BE SHINING Study Group

doi: 10.1111/jdv.70350

Psoriatic Arthritis

Clinical Significance of Gut Microbiota Community Types for Long-term Response to Fecal Microbiota Transplantation in Patients with Psoriatic Arthritis

Arthritis Rheumatol

Qin P, Kragsnaes MS, Holm DK, Horn HC, Nilsson AC, Kjeldsen J, Kristiansen K, Ellingsen T

doi: 10.1002/art.43359

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Further Publications Immunology

Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study

J Autoimmun

Bustaffa M, Bella S, Bayindir Y, Amaryan G, Gallizzi R, Papadopoulou-Alataki E, Fabio G, Assalia N, Amarilyo G, Bakkaloglu S, Jesenak M, Breda L, Anton J, Legger E, Alessio M, Simonini G, Rigante D, Obici L, Kuemmerle-Deschner J, Kasapcopur O, Insalaco A, Glerup M, Frenkel J, Brunner J, Horneff G, Sánchez-Manubens J, Cantarini L, Spagnolo A, Alataki S, Carrabba M, Belder N, Porreca A, Caorsi R, Ruperto N, Gattorno M, Ozen S, Eurofever Registry

doi: 10.1016/j.jaut.2025.103421

Systemic Lupus Erythematosus

Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up

Rheumatology (Oxford)

Michelakis IE, Kapsia E, Boletis JN, Marinaki S, Sfikakis PP, Tektonidou MG

doi: 10.1093/rheumatology/keaf677

Psoriasis

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

JAMA Dermatol

Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB

doi: 10.1001/jamadermatol.2025.6055

Acne

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

J Eur Acad Dermatol Venereol

Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, Martorell A, Kirby B, Alavi A, Hayama K, Khattri S, Gulliver W, Sayed CJ, Davis L, Rolleri RL, Crater C, Pansar I, Lambert J, Zouboulis CC

doi: 10.1111/jdv.70356

Rheumatoid Arthritis

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Lancet Rheumatol

Cope AP, Jasenecova M, Vasconcelos JC, Qureshi S, van Schie KA, Filer A, Raza K, D'Agostino MA, McInnes IB, Siebert S, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Mankia K, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga TWJ, Toes REM, Georgiou E, Kelly J, Murphy C, Prevost AT, ALTO Study Investigators

doi: 10.1016/S2665-9913(25)00371-6

Related content

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

Clinical Significance of Gut Microbiota Community Types for Long-term Response to Fecal Microbiota Transplantation in Patients with Psoriatic Arthritis

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study

Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial